アニュアル・レポート2008
|
|
|
- ゆみか かに
- 5 years ago
- Views:
Transcription
1 アニュアル レポート 2008
2 Transformation and Growth MGI % 2, % hhc 2, % 7,343 7, % 1, % 1987/3 CONTENTS PERFORMANCE & STRATEGY & 17 Eisai RD hhc MANAGEMENT SYSTEM CSR FINANCIAL SECTION
3 DLP 4 MGI 1.5 Eisai Co., Ltd. PERFORMANCE & STRATEGY DLP /3 2012/3 2017/3 CORPORATE INFORMATION MGI PHARMA, INC. Corporate Social Responsibility: CSR
4 Eisai Co., Ltd. PERFORMANCE & STRATEGY Aloxi 6 TNF 5 81mg 330mg NICE 4 BB 2 PT-INR XS 3 KL6 SA BB CBBC 1 TNF mg D10mg MGI BAN NICE 7 MGI R&D KES TNF Aloxi 8
5 ,002 5,330 6,013 6,741 7,343 7, , , (170) ,083 2,254 1, ,195 4,596 5,192 5,525 4, ,158 6,627 7,472 7,921 11, , ROE (3.4) ROA (1.8) DOE EPS (59.80) EPS Eisai Co., Ltd. PERFORMANCE & STRATEGY 03 (1) (2) (3) 11 (4) 1EPS EPS GAAP GAAP GAAP 8,000 6,000 5,002 5,330 6,013 6,741 7,343 1,200 1, ,053 1, , , % 2, , ,100 1, , , EPS DOE % DOE 0
6 Eisai Co., Ltd. PERFORMANCE & STRATEGY 04 CEO
7 hhchuman health care 1 DNA Eisai Co., Ltd. PERFORMANCE & STRATEGY MGI39 Aloxi Eisai Corporation of North AmericaEisai Europe Ltd.Eisai China Inc.Eisai Asia Regional Services Pte Ltd.
8 Eisai Co., Ltd. PERFORMANCE & STRATEGY IT E7389E AMPAE
9 200837, MGI GAAP MGI E rd Eisai Co., Ltd. PERFORMANCE & STRATEGY , , PPI1, ,254MGI 1, , H 6 FDA E E2007AMPA 8 2 5B 6 FDA 7Lipid A 81AMPA
10 Eisai Co., Ltd. PERFORMANCE & STRATEGY 08 E FDA E MORAb MGI DNA / DNA TNF mg IgG1 12 EU10 13 TNF
11 Eisai Co., Ltd. PERFORMANCE & STRATEGY V , , /3 I , /3 II , /3 III97-01 IV / , /3 6, /3 2,000 2,000 1,200
12 Eisai Co., Ltd. PERFORMANCE & STRATEGY DLP MGI DLP DLP MGI DLP 6 DLP MGI1 2 Global Policy & Strategy Council JBHQ P1 MGI Global Medical & Marketing Services MR9201, (083 MGI / 20083
13 CAGR 9% 2007/3 6, /3 2012/3 CAGR 14% 2007/3 1, /3 2008/3 2012/3 CAGR 13% 2007/3 1,053 7,343 1, ,254 GAAP 2, /3 3, /3 3, /3 4, /3 2, /3 3, /3 4, / /3 544 Eisai Co., Ltd. PERFORMANCE & STRATEGY /3 177GAAP 2012/3 1, /3 2012/3 1,108 2, /3 237 CAGR 11% 2008/ / /3 170GAAP 2008/ /3 1, MGIGAAP GAAP 2012/3 2007/3 3, /3 4, / , / /3 1,055 ROE 2007/3 13.2% 2008/3 3.4% ROE DOE 2007/3 6.4% 2008/3 7.4% 2012/3 8.0+% DOE DPR 2007/3 48.4% 2008/3 GAAP GAAP GAAP DPR
14 Eisai Co., Ltd. PERFORMANCE & STRATEGY 12 MGI MGI MGI Aloxi DNA MGI E7389E7974 E6201DacogenTargretinPanretin Gliadel Wafer Irofulven E7070E7107 E7820E7080 GPI21016 MORAb003MORAb009 MORAb004MORAb028 ONTAK DNAamolimogeneZYC300 E6020 Aloxi Saforis AKR501 GCP MGI
15 MGI MGI MGI MGI Aloxi HT3 5-HT Dacogen DNA Eisai Co., Ltd. PERFORMANCE & STRATEGY 13 MGI Aloxi Dacogen Gliadel Wafer Aloxi fospropofol disodium Aloxi Saforis Dacogen5 Dacogen Dacogen amolimogene AKR-501 Irofulven ZYC300 GPI21016 GCP decitabine 20088
16 Eisai Co., Ltd. PERFORMANCE & STRATEGY MGI MGI MRMGI MGI
17 2 70 MGI DNA AloxiDNADacogen Gliadel WaferMGI E2007E7389 E5564 fospropofol disodium ONTAK MORAb-003 MGIDNAamolimogene Eisai Co., Ltd. PERFORMANCE & STRATEGY 15 TargretinPanretinAloxi DacogenGliadel Wafer fospropofol disodiume2007 E7389E5564 ONTAK MORAb-003MORAb-009 amolimogenezyc300 E7389 E7820 MORAb-003 E7080 fospropofol disodium MORAb-009 Aloxi Dacogene amolimogene E2012 E5555 MGI 4,
18 Eisai Co., Ltd. PERFORMANCE & STRATEGY 16 Q5 Q A Ahhc Q A
19 Eisai RD Eisai Co., Ltd. PERFORMANCE & STRATEGY 17
20 Eisai Co., Ltd. PERFORMANCE & STRATEGY MGI MGI POCProof of Concept:
21 4 CEO 4E7389 E5564E2007AMPA E73892nd3rd E5564 E2007 Eisai Co., Ltd. PERFORMANCE & STRATEGY 19 4DLP CEO CEO E2007 E7389 E5564
22 Eisai Co., Ltd. PERFORMANCE & STRATEGY 20 4 E7389 E B rd FDA 3rd H 1 FDA 1: FDA AMPAE2007 AMPA AMPA 2 E2007 E E TLR :Lipid A
23 E0735 E2020 E3810 E0103 Aloxi E3270 D2E7 E7337 E3810 Aloxi E MGI TNF MGI Eisai Co., Ltd. PERFORMANCE & STRATEGY 21 1 E E AMPA AS E2080 E E0302 / E SEP-190 GABA-A 20113
24 Eisai Co., Ltd. PERFORMANCE & STRATEGY 22 2 E POC E MORAb-003 IgG1 MORAb-009 IgG1 Dacogen DNA E7373 MDS Irofulven E7850 AKR-501 amolimogene E7101 DNA HPVDNA MGI MDS MDS MGI MGI fospropofol MGI E2083 MGI Saforis E6014 MGI 3 TNF D2E E5564 POC E E6201 MEK-1/MEKK-1 T
25 4 / E HT Eisai Co., Ltd. PERFORMANCE & STRATEGY 23 5 KES DNAB E
26 Eisai Co., Ltd. PERFORMANCE & STRATEGY 24 The Americas MGI MGI201231,000 1, , , , PPI OTC PPI OTC Eisai Inc. 400 MR MR
27 Japan ,200 XS 42 XS mg 20086TNF 40mg0.8mL Eisai Co., Ltd. PERFORMANCE & STRATEGY MR TNF MRMR
28 Eisai Co., Ltd. PERFORMANCE & STRATEGY 26 Europe EU PPI B EKC EKC EKC
29 Asia, Oceania and the Middle East Eisai Clinical Research Singapore Pte. Ltd Eisai Co., Ltd. PERFORMANCE & STRATEGY 27 China 3 MR CRM B
30 Eisai Co., Ltd. PERFORMANCE & STRATEGY 28 hhc hhc MR MR hhc
31 hhc hhc hhc hhc 10,700 hhchhc hhc V Eisai Co., Ltd. MANAGEMENT SYSTEM 29
32 Eisai Co., Ltd. MANAGEMENT SYSTEM 30 DOE 20083DOE DOE IR ,500 5,000 3,500 2, /3 DOE=ROEx DPS / / / /3 2005/ % TOPIX 95.6% /3 0.2% 2.5% / /3 DOE% 02, /3 2007/3 2008/3 00, % % TOPIX 96.9% 27,000 02,500 22,000 02,000 17,000 01,500 12,000 00,1,000 07,000 0,0500 % 15, , , , , , , , , , , %10 0.1% 2.0% 0.7% % 13.8% 31.1% 38.7% 4.5% 7.7% % 17.7% 25.8% 39.7% 5.2% 7.7%
33 CSR CSR CSR CSR ENW ISO14001 ENW e-enw Eisai Co., Ltd. MANAGEMENT SYSTEM 31
34 Eisai Co., Ltd. MANAGEMENT SYSTEM CEO
35 Eisai Co., Ltd. MANAGEMENT SYSTEM CSA CSA
36 Eisai Co., Ltd. MANAGEMENT SYSTEM 34 1, , , , ,210 12, , ,774 9, , , , , , , , , , , (40,000)241,280(128,000)1,680(168,000) 1(991) 5.
37 Q A Q117 A117 hhc 1 Q A Eisai Co., Ltd. MANAGEMENT SYSTEM 35 ROE 4 1,
38 Eisai Co., Ltd. MANAGEMENT SYSTEM 36 CEO CEO CEO hhc&compliance IR IR IR
39 LLP LLP ICSID LLP Eisai Co., Ltd. MANAGEMENT SYSTEM 37
40 Eisai Co., Ltd. MANAGEMENT SYSTEM 38 CEO CFO COO COO HR CFO IR
41 CONTENTS Eisai Co., Ltd. FINANCIAL SECTION
42 Eisai Co., Ltd. FINANCIAL SECTION ,343(8.9)177(83.1) ,910(15.1) 1,759(0.9) MGI PHAR- MA, INC MGI PHARMA, INC. SFAS GAAP 2 1, , GAAPGenerally Accepted Accounting Principles GAAP , , , , , , , (53) 1, , (170) % % 8,000 6,000 4,000 5,002 5,330 6,013 6,741 7, , EPS ROE ROA
43 1 1, ,239(3,318 )4,538(1,089) 3 4,4891, (29.8) (170) 706 (876) (2) (1)... 1, , MGI PHARMA, INC. 1, , , ,2541, Eisai Co., Ltd. FINANCIAL SECTION 41 1DOE % % ,000 2,910 2, ,400 1,800 1, ,529 1,965 1,743 1,629 1,545 1,416 1,290 1,323 1,759 2,100 1, ,083 2, DOE
44 Eisai Co., Ltd. FINANCIAL SECTION MGI PHARMA, INC. SFAS , MGI PHARMA, INC , (25.4) , MGI PHARMA, INC , , MGI PHARMA, INC ,118(9.0 )MGI PHARMA, INC.198 (81.7) Eisai SA/NV % 1, , , % 3.8% 2.7%0.4% 3.1% 3.8% 7.4% % 96.9% 39.8% 46.2% 42.6%
45 , ,7014,407 4,5381,089 4,4891, (29.8) 732(79 ) Eisai Co., Ltd. FINANCIAL SECTION 43 1, ,0917 2, MGI PHARMA, INC. 11,2393,318 MGI PHAR- MA, INC.Morphotek, Inc ,764 4,212MGI PHARMA, INC.Morphotek, Inc.4, , , % (27) (235) (384) (59) (149) (79) 4,891 (4,366) (4,159) (4,445)
46 Eisai Co., Ltd. FINANCIAL SECTION , ,090 $1,199, ,930 8,964 49, ,797 7,460 47, , ,711 1,673, ,537 4, , (308) (352) (3,080)... 58,091 52, , ,399 33, , ,824 8, , , ,210 4,155, ,832 18, , , ,462 1,596, , ,771 1,500, ,801 4, , , ,177 3,502, (203,189) (198,334) (2,031,890) , ,842 1,470, , , , ,750 45: ,671 4,530 1,786, ,247 45,986 1,642, , , ,424 12, , ,650 32, , ,402 10, , , ,061 5,612, ,123, ,114 $11,239,390
47 , $ 3,628, ,644 1,094 16, ,663 18, , ,932 57, , ,175 52, , ,088 22, , ,324 35, , ,542 5,185 55, , ,779 5,431,910 Eisai Co., Ltd. FINANCIAL SECTION , , ,245 33, , , , ,462 4, , ,956 37,636 1,269, , ,416 6,701, : 1,100,000, ,566, ,985 44, , ,966 55, , , , ,632 4,159, ,509 19,859 95, (38,868) 4,984 (388,680) ,665, ,437, (39,694) (42,219) (396,940) , ,759 4,494, ,374 9,938 43, , ,698 4,537, ,123, ,114 $11,239,390
48 Eisai Co., Ltd. FINANCIAL SECTION , ,111 $7,342, , ,302 1,188, , ,809 6,154, , ,249 3,723, , ,296 2,254, , , , ,188 6,086 61, (762) (65) (7,620)... (4,138) (729) (41,380)... 2,203 1,657 22, (1,095) (1,147) (10,950)... (1,421) (12) (14,210)... (1,071) (718) (10,710)... (96) 5,071 (960)... 17, , , ,492 47, , (2,304) (8,513) (23,040)... 37,188 39, , (2,522) 522 (25,220)... (17,012) 70,614 $ (170,120) EPS... (59.80) $(0.59) 1* *
49 ,566 (12,437) 44,985 55, ,632 19,859 4,984 (42,219) 552,759 9, , (17,012) (17,012) (17,012)... (36,938) (36,938) (36,938) ,743 2,798 4,542 4, (51) (273) (273) (273) * () (10,350) (43,852) (53,941) (5,563) (59,505) ,566 (11,665) 44,985 56, ,961 9,509 (38,868) (39,694) 449,416 4, ,791 * Eisai Co., Ltd. FINANCIAL SECTION ,566 (10,692) 44,985 55, ,025 20,327 1,567 (31,913) 519, , ,296 9, ,614 70,614 70, (29,913) (29,913) (29,913) (94) (2,023) (11,194) (11,194) (11,194) () (467) 3,416 3, , ,566 (12,437) 44,985 55, ,632 19,859 4,984 (42,219) 552,759 9, , $449,850 $552,220 $2,940 $4,696,320 $198,590 $ 49,840 $(422,190) $5,527,590 $99,380 $5,626, (170,120) (170,120) (170,120)... (369,380) (369,380) (369,380)... 17,430 27,980 45,420 45, (2,730) (2,730) (2,730) *... 2,810 2,810 2,810 ()... 2,610 (103,500) (438,520) (539,410) (55,630) (595,050)... $449,850 $569,660 $5,560 $4,159,610 $ 95,090 $(388,680) $(396,940) $4,494,160 $43,740 $4,537,910 *
50 Eisai Co., Ltd. FINANCIAL SECTION , ,334 $ 176, (49,324) (48,948) (493,240)... 34,559 26, , , , (2,203) (1,657) (22,030)... 1, , , , (2,352) (11,807) (23,520)... (2,777) (5,481) (27,770) (6,312) 3, (1,731) 7,600 (17,310)... (7,949) 7,040 (79,490)... (7,170) (3,801) (71,700)... 3,717 6,470 37, ,242 81, , ,415 10, , (39,227) (22,549) (392,270)... (14,508) (6,009) (145,080)... 10,363 8, , (6,931) (20,150) (69,310) (435,504) (4,355,040)... (24,279)... (1,054) (702) (10,540)... (476,447) (55,212) (4,764,470) ,580 (188) 3,625, , , (36,938) (29,913) (369,380)... (11,060)... (275) 541 (2,750) ,365 (40,620) 3,753, (23,299) 2,456 (232,990)... (51,140) (12,188) (511,400) , ,278 1,710, , ,090 $1,199,500
51 = a Eisai Co., Ltd. FINANCIAL SECTION 49 b 3 c d e
52 Eisai Co., Ltd. FINANCIAL SECTION 50 f g h i j 5 5 k l m
53 n 1 2 o Eisai Co., Ltd. FINANCIAL SECTION 51 p q ,512 2,133 $ 25, ,403 6,591 14, , , ,930 8,964 $ 49, ,807 77,064 $568, ,797 28, , ,528 1,029 45, ,029 3,692 50, , , ,488 $891,680
54 Eisai Co., Ltd. FINANCIAL SECTION ,298 20,338 (3,829) 56,807 43,220 34,287 (443) 77, ,793 (152) 3, , (29) 1,901 1, (16) 1, , (218) 24,238 35, (297) 35, $402,980 $203,380 $(38,290) $568, ,930 (1,520) 36, , (290) 19, ,000 2,560 (2,180) 242, ,204 2,293 $82, ,203 1,657 22,030 ) ,013 1,403 $10,130 $ 14, ,402 9,699 14,020 96, , , ,957 29, ,374 24,200 $53,740 $242, amorphotek, Inc.MOR 1) i)... Morphotek, Inc. ii)... iii)... iv)
55 v)... Eisai Corporation of North AmericaECAMAB Acquisition Corporation MAC100%MOR MACMOR MORECA100% vi)... Morphotek, Inc. vii) % 2) ) ) Eisai Co., Ltd. FINANCIAL SECTION 53 5) ) bmgi PHARMA, INC.MGI 1) i)... MGI PHARMA, INC. ii)... iii)... iv) v)... ECAJaguar Acquisition CorporationJAC100% MGI JACMGIMGI ECA100% vi)... MGI PHARMA, INC. vii) % 2) )... 3, ,943
56 Eisai Co., Ltd. FINANCIAL SECTION 54 4) i)... 1,744 ii) iii) SFAS142 5) , , , ,136 6) ) , ) MGI a 1) i)... ii)... iii).... iv)... PARSARProbe alternation link self-assembly reaction % ) 1,6245
57 $ $ % %8% %5.75% % Eisai Co., Ltd. FINANCIAL SECTION MGI PHARMA, INC , % 8308, % ,577 27,833 $ 405, , , ,167 22, , ,624 5, , ,965 5,872 59, ,432 4,492 44, ,085 6,273 40, ,303 13, , ,720 11, , (7,380) (5,723) (73,800) ,379 82,816 1,213, , , , , ,976 13,854 69, ,148 3,252 31, ,579 17, , ,800 65,709 $ 388,000
58 Eisai Co., Ltd. FINANCIAL SECTION % 41.0% (1.1) (0.2)... (30.4) (5.1)... (26.1) (1.5) (7.8) (0.7) % 35.5% 9. 45% 55% (113,560) (113,860) $(1,135,600)... 86, , , ,702 (11,347) 97, (6,517) (9,149) (65,170)... (24,104) (31,768) $ (241,040) ,664 3,867 $46, ,736 2,723 27, (3,316) (3,380) (33,160)... (2,252) 423 (22,520)... (2,642) (2,643) (26,420)... 1,585 1,314 15, ,306 $ 7, % 2.5% % 4.0% ,14021,4001,330
59 , , $30.90) , , ($26.68) , , ($31.65) , , ($25.20) , , ($31.70) , , ($38.20) , , ($53.00) , , ($54.80) Eisai Co., Ltd. FINANCIAL SECTION ,600 78, ,800 86, , , , ,000 4,400 10,000 9,000 14,000 6,000 26,400 53,200 68, ,800 72, , , , ,000 4,662 4,915 4,280 4,213 4,560 5, ($46.62) ($49.15) ($42.80) ($42.13) ($45.60) ($52.49) 1, ($11.61) ($9.91) % /
60 Eisai Co., Ltd. FINANCIAL SECTION amorphotek, Inc. 2,548 $ 25, ,350 55, ,050 (17,433) (174,330) (842) (8,420) , , ,200 Morphotek, Inc... (2,485) (24,850) Morphotek, Inc ,234 $382,340 bmgi PHARMA, INC ,305 $ 463, ,075 10, ,244 3,252, ,228 32, (15,519) (155,190)... (31,451) (314,510)... (2,377) (23,770)... 87, , (3,443) (34,430) ,505 4,105,050 MGI PHARMA, INC... (13,235) (132,350) MGI PHARMA, INC. 397,269 $3,972, a ,694 3,952 $36, ,387 1,814 13, ,290 2,121 $22,900
61 b ,069 $ 8, ,457 1,102 14, ,319 2,172 $23, $ 20 c ,247 1,161 $12, ,187 1,095 11, Eisai Co., Ltd. FINANCIAL SECTION ,311 2,204 $ 33, ,676 13, ,760 18,988 15,994 $189, ,400 84,346 5,053 14,469 14, $894,000 $843,460 $50, ,043 1,050 (7)
62 Eisai Co., Ltd. FINANCIAL SECTION a ,844 22, , ,936 21, , ,860 (21,047) ,198 (21,428) ,030 43,303 (21,047) 734, ,167 42,373 (21,428) 674, ,209 41,383 (17,056) 716, ,107 40,662 (16,922) 568, ,820 1,919 (3,990) 17, ,059 1,710 (4,506) 105, ,026,602 31,640 65,696 1,123, ,788 31, , , , ,559 25, , , ,047 50, , $7,118,440 $224,420 $7,342,860 1, ,600 $(210,470)... 7,120, ,030 (210,470) 7,342, ,922, ,830 (170,560) 7,165, $ 198,200 $ 19,190 $ (39,900) $ 177, $10,266,020 $316,400 $656,960 $11,239, ,100 7,690 2, , ,331,950 4,150 4,360 4,340,470
63 b , ,396 54,416 27, , ,071 50,650 27, (183,008) , ,046 81,566 27,953 (183,008) 734, , ,930 79,767 22,336 (179,742) 716, ,482 (66,883) 1,799 5,617 (3,265) 17, , ,108 58,876 27,441 (455,914) 1,123, , ,411 54,774 23, , ,303 36,896 18, (141,513) , ,307 73,077 23,714 (141,513) 674, , ,545 69,017 19,693 (137,131) 568, ,802 28,761 4,059 4,021 (4,381) 105, , ,123 57,427 23, ,114 Eisai Co., Ltd. FINANCIAL SECTION $3,126,560 $3,393,960 $544,160 $278,170 $ 7,342, ,050, , ,500 1,360 $(1,830,080) ,177,270 3,900, , ,530 (1,830,080) 7,342, ,372,450 4,569, , ,360 (1,797,420) 7,165, $ 804,820 $ (668,830) $ 17,990 $ 56,170 $ (32,650) $ 177, $9,304,270 $5,631,080 $588,760 $274,410 $(4,559,140) $11,239,390 c ,391 73,100 31, , ,005 72,218 26, , , , % 10.0% 4.2% 61.9% 46.3% 10.7% 3.9% 60.9% $3,503,910 $731,000 $310,590 $4,545, ,342,860
64 Eisai Co., Ltd. FINANCIAL SECTION (17,012) 284,487 (59.80) $(0.59) , , , , * a % 2...2, % MGI PHARMA, INC MGI PHARMA, INC MGI PHARMA, INC.
65 MGI PHARMA, INC. b ,518 $185,180 c , Eisai Co., Ltd. FINANCIAL SECTION
66 Eisai Co., Ltd. FINANCIAL SECTION (a) Eisai Co., Ltd. Annual Report 2008 INDEPENDENT AUDITORS REPORT
67 Eisai Co., Ltd. CORPORATE INFORMATION
68 Eisai Co., Ltd. CORPORATE INFORMATION 66 5MGI PHARMA, INC. MGI PHARMA, INC Hatch- Waxman IT IT E 17 18
69 Eisai S.A. BIODIM MGI Eisai Inc. Eisai Medical Research Inc Eisai Inc , ISO Eisai Co., Ltd. CORPORATE INFORMATION
70 Eisai Co., Ltd. CORPORATE INFORMATION 68 2 Eisai Corporation of North America 100 Tice Boulevard Woodcliff Lake, New Jersey 07677, U.S.A. TEL: FAX: Eisai Research Institute of Boston Inc. 4 Corporate Drive Andover Massachusetts 01810, U.S.A. TEL: FAX: Eisai Machinery U.S.A. Inc. 90 Boroline Road, Allendale New Jersey 07401, U.S.A. TEL: FAX: Eisai Inc. 100 Tice Boulevard Woodcliff Lake, New Jersey 07677, U.S.A. TEL: FAX: A Eisai Inc./Research Triangle (RTP) 900 Davis Drive, P.O. Box RTP, North Carolina 27709, U.S.A. TEL: FAX: Eisai Medical Research Inc. 55 Challenger Road, Ridgefield Park New Jersey , U.S.A. TEL: FAX: Morphotek, Inc. 210 Welsh Pool Road, Exton, Pennsylvania U.S.A. TEL: FAX: Eisai Europe Ltd. Titan Court, 3 Bishop Square, Hatfield, Hertfordshire AL10 9NE, U.K. TEL: FAX: Eisai London Research Laboratories Ltd. Bernard Katz Building University College London Gower Street, London WC1E 6BT, U.K. TEL: FAX: = Eisai Ltd. Titan Court, 3 Bishop Square, Hatfield, Hertfordshire AL10 9NE, U.K. TEL: FAX: A Eisai Manufacturing Ltd. Titan Court, 3 Bishop Square, Hatfield, Hertfordshire AL10 9NE, U.K. TEL: FAX: B Eisai GmbH Lyoner Strasse 36 D Frankfurt am Main, Germany TEL: FAX: Eisai GmbH Niederlassung Oesterreich Saturn Tower, Leonard-Bernstein-Strasse 10 A-1220 Wien, Austria TEL: FAX: Eisai GmbH Magyarorszagi Kereskedelmi Kepviselete Frangepan utca 5-7, H-1139 Budapest, Hungary TEL: FAX: Eisai GmbH Organisational Branch Holusicka 2253/ Prague 4 - Chodov Czech Republic TEL: FAX: C Eisai Machinery GmbH Mathias Brueggen Strasse 142 D Koeln, Germany TEL: FAX: D Eisai S.A.S. Tour Manhattan, 5-6 Place de I Iris Paris La Défense 2 Cedex, France TEL: FAX: E Eisai B.V. Strawinskylaan 909, 1077 XX Amsterdam, The Netherlands TEL: FAX: F Eisai Farmacéutica S.A. C/Arturo Soria 336, 3 a Planta Madrid, Spain TEL: FAX: G Eisai S.r.l. Via dell Unione Europea San Donato Milanese (MI), Italy TEL: FAX: H Eisai Pharma AG Schaffhauserstrasse 611, 8052 Zurich, Switzerland TEL: FAX: I Eisai AB Svardvagen 3a, Danderyd P.O. Box Stockholm, Sweden TEL: FAX: J EF-Eisai Farmacêutica, Unipessoal Lda. Lagoas Park, Edifício 5A, Piso Porto Salvo, Portugal TEL: FAX: K PT Eisai Indonesia Sentral Senayan II, 12 Floor, Jl. Asia Afrika No. 8, Senayan, Jakarta 10270, Indonesia TEL: FAX: B Bogor Factory JI. Lanbau Desa Karang Asem Barat, Kecamatan Citeureup, Kabupaten Bogor Jawa-Barat 16810, Indonesia TEL: FAX: L Eisai Asia Regional Services Pte. Ltd. 152 Beach Road #15-05/08, Gateway East Singapore TEL: FAX: M Eisai (Singapore) Pte. Ltd. 152 Beach Road #15-05/08, Gateway East, Singapore TEL: FAX: N Eisai Clinical Research Singapore Pte. Ltd. 152 Beach Road #15-05/08, Gateway East Singapore TEL: FAX: B D C O Eisai (Malaysia) Sdn. Bhd. Lot 6.1, 6th Floor, Menara Lien Hoe No. 8, Persiaran Tropicana Petaling Jaya, Malaysia TEL: FAX: P Eisai (Thailand) Marketing Co., Ltd. 6th Floor, GPF Witthayu Tower A 93/1 Wireless Road, Bangkok 10330, Thailand TEL: FAX: Q HI-Eisai Pharmaceutical Inc. 20th Floor, Multinational Bancorporation Centre 6805 Ayala Avenue, 1226 Makati City, Philippines TEL: FAX: R Eisai (Hong Kong) Co., Ltd. Room 2008, Fortress Tower 250 King s Road, North Point Hong Kong, China TEL: FAX: S Eisai Korea Inc. 10F Revessant, Samseong-dong, Gangnam-gu Seoul , Korea TEL: FAX: T M 9th Floor, No. 18, Chang An E. Road, Sec. 1 Taipei, Taiwan TEL: FAX: C L No. 54, Gong-Yeh West Road, Guan Tyan Hsiang, Tainan Hsien, Taiwan TEL: FAX: U 39th-40th Floor, Park Place, No.1601, Nanjing Xi Road, Shanghai City, China TEL: FAX: D Bai Yu Road #32 Suzhou Industrial Park Suzhou, Jiangsu Province, China TEL: FAX: V Eisai Pharmaceuticals India, Pvt. Ltd. 1st Floor, B-Wing, Marwah Centre Krishanlal Marwah Marg, Andheri (East) Mumbai , India TEL: FAX: W Eisai Pharmatechnology & Manufacturing Pvt. Ltd. D.No /1, Plot No 135, Sea Breeze Villa, Visalakshi Nagar Main Road, Visakhapatnam. PIN , AP. India TEL: FAX:
71 A MI R&D3F TEL: FAX: TEL: FAX: TEL: FAX: TEL: FAX: TEL: FAX: F TEL: FAX: Eisai Co., Ltd. CORPORATE INFORMATION TEL: TEL: FAX: TEL: FAX: F TEL: FAX: TEL: FAX: F TEL: FAX: F TEL: FAX: TEL: FAX: TEL: FAX: TEL: FAX: TEL: FAX: TEL: FAX: TMM6F TEL: FAX: TEL: FAX: TEL: FAX: TSK3F TEL: FAX: TEL: FAX: C3F TEL: FAX: F TEL: FAX: F TEL: FAX: F TEL: FAX: F TEL: FAX:
72 Eisai Co., Ltd. CORPORATE INFORMATION 70 K2 G R 111 R TNF MRI 5-HT1B1D Ca M M H2 /DS
73 Eisai Co., Ltd. CORPORATE INFORMATION 71 S BB B2 BB C C L- BB B2 B6B1C BB B2 BB 2 S S E PIVKA- KL-6 ucoc K CARF XS G
74 Eisai Co., Ltd. CORPORATE INFORMATION 72 C E O
75 Eisai Co., Ltd TEL ,985 4,13710, ,566,949 66,930 UFJ JP Morgan Chase Bank, N.A. 4 New York Plaza, New York, NY10004 U.S.A. Eisai Co., Ltd. CORPORATE INFORMATION MS TEL: FAX: IR
76
アニュアル レポート2011
2011 We re Transforming WHO hhc hhc hhc hhc 1820 1910 Giving First Thought to Patients Contents 02 06 08 08 DLP 10 1 2 3 4 5 12 14 18 20 28 30 CSR 34 35 40 43 70 72 75 IT Corporate Social Responsibility
1) IT IR CSR 120 DAIWA SECURITIES GROUP ANNUAL REPORT 2010
p120 p126 p130 p131 p133 DAIWA SECURITIES GROUP ANNUAL REPORT 2010 119 1) 2010 7 1 IT IR CSR 120 DAIWA SECURITIES GROUP ANNUAL REPORT 2010 121 DAIWA SECURITIES GROUP ANNUAL REPORT 2010 CEO COO SMBC PI
95 SMBC
94 CEO CIO S ( CEO ) 2002 6 26 95 SMBC 2002 6 26 2002 6 26 96 2002 7 1 97 2002 7 1 98 2002 7 1 100-8155 6 4 03 3243-2626 100-0011 2 2 03 3508-8111 102-0073 2 3 03 3221-9811 104-0028 8 1 03 3243-3811 104-0061
1) 2011 7 1 104
P104 P110 P114 P115 P117 103 1) 2011 7 1 104 22011 7 1 CEO COO CFO CRO CIO 105 1) 2011 7 1 106 22011 7 1 107 108 1) 2011 7 1 109 22011 7 1 2011 7 1 100-6755 1 9 1 03 5555-7555 060-8601 3 7 011 214-6111
野村証券グループレポート2001 (PDF)
2 5 6 8 9 10 20 22 24 26 28 30 33 1 2 3 4 6 8 Nomura Group 5 6 7 8 10 10 14 20 22 Our Business 24 9 10 0 5 10 15 20 25 30 '00.3 '01.3 95.3 90.3 85.3 0 7,000 14,000 21,000 28,000 35,000 42,000 0 100 200
CSR ERX ERX
Corporate Report 2010 2010 3 100 1959 1 2 4 6 7 8 9 10 12 14 18 20 22 23 24 26 27 28 30 50 50 100 100 100 CSR 100 1960 1962 1 1969 1974 1985 1993 2003 ERX ERX 50 2009 Corporate Report 2010 1 50 100 50
2004 3 1963 1 2 4 2004 MISUMI It s about TIME QCT 8 12 CSR 14 16 17 6 18 19 24 39 40
2004 2004 3 MISUMI It s about TIME 2004 3 1963 1 2 4 2004 MISUMI It s about TIME QCT 8 12 CSR 14 16 17 6 18 19 24 39 40 MISUMI Corporation ANNUAL REPORT 2004 2003 32004 3.................................................
Nikon アニュアルレポート 2000
2000 1999 2000 371,801 305,765 $ 3,503 21.6% 18,434 ( 8,741) 174 7,770 (18,233) 73 21.01 (49.29) $ 0.20 5.00 3.00 0.05 66.7% 502,175 474,965 $ 4,731 5.7% 166,495 160,991 1,568 3.4% 1 2 3 4 5 6 NSR-S204B
C O N T E N T S
ALL NIPPON AIRWAYS CO., LTD. 2003 Fifty Years of Progress in Air Transportation C O N T E N T S Focused on the Next 50 Years 50 1 2 3 Q1 A1 4 Focused on the Next 50 Years 5 Q2 A2 6 Focused on the Next
EPSON Safety Instructions Manual
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 < EUROPE, MIDDLE EAST & AFRICA > ALBANIA : ITD Sh.p.k. http://www.itd-al.com AUSTRIA : Epson Deutschland GmbH http://www.epson.at BELGIUM : Epson Europe B.V. Branch
1 20 2 26 4 28 6 30 10 32 12 33 14 74 75 1 2 0 6,000 7,000 5,000 4,000 3,000 2,000 1,000 2015 2012 2013 500 600 700 400 300 200 100 0 10 12 14 8 6 4 2 2015 2012 2013 2014 6,016 2014 6,252 2016 7.1 8.7
NNA Since 1989
NNA Since 1989 NNA 2011 1945 NHK 17 1 9 199578 1 1989 8 2016 4 7,000 1 2017 19.5 189 UFJ NNA JAPAN CO., LTD. 1989 8 WIN HONEST PLANNING LIMITED 1992 6 1994 9 1995 4 6 8 1996 8 10 1998 1 4 WebNNA PLUS 1999
80% No.1 3... 1... 2... 5... 5... 9... 13... 14... 22... 22... 23... 24... 26... 27... 53... 54
2005 2005 3 Looking ahead 80% No.1 3... 1... 2... 5... 5... 9... 13... 14... 22... 22... 23... 24... 26... 27... 53... 54 20052004 3 2005 3 2004 3 2005/2004 2005 3... 92,696 89,858 3.2% $ 863,175... 18,982
44 48 2 3 5 kg/m 3 % (GPa) MPa GPa MPa m x -6 / W/(m K) J/(kg K) V/m cm (X -4 ) (X -4 ) JIS C24 JIS C24 JIS R6 JIS R6 JIS R62 JIS R67 JIS R68 JIS R6 JIS R6 JIS C24 A-479 99% White 3.8 3 5.2 3 36.23 3 4
aozora.…y…›.pdfŠp
AOZORA BANK 2 0 0 1 CONTENTS 1 2 4 6 10 11 12 13 Profile AOZORA BANK 2 0 0 1 02-03 133 143 153 71,100 49,400 52,300 559 684 765 423 453 451 136 231 314 11.79% 11.78% 11.55% 13.43% 12.92% 12.33% 1 166
...j.N.. AR2005(.O..)
1984 expansion 1998 world 2001 2005 transformation FAST RETAILING CO., LTD. our group UNIQLO COMPTOIR DES COTONNIERS FOOT PARK ASPESI national standard Theory business model products Do you know?
90 91 92 94 90 8 91 3131, 31st Floor, China World Trade Center No.1 Jian Guo Men Wai Avenue Beijing 100004, The People's Republic of China TEL: 86-10-6505-8989, 38258, 1196, 1197 FAX: 86-10-6505-3829,
Traditional View The Red that You ve never seen CYAN : 10 MAGENTA : 100 YELLOW : ADK VISION VI Visual Identity ADK ADK Active Red Ac
2014 2014 12 THE DIFFERENCE IN RED Traditional View The Red that You ve never seen CYAN : 10 MAGENTA : 100 YELLOW : 90 2013 ADK VISION 2020 2014 VI Visual Identity ADK ADK Active Red Active Red ADK BLACK
PREFACE: The Origins of Quality A I D A E n g i n e e r i n g, LT D.
PREFACE: The Origins of Quality A I D A E n g i n e e r i n g, LT D. Manufacturing In the Age of The Environment NS1-1500(D) +LFL 200 188 100 wh 97 1 1.67 2 100 kw/h A n n u a l R e p o rt 2 0 1 0 1 PREFACE:
Eyeing the Next Stage
Eyeing the Next Stage 2014 3 2014 Our Values CONTENTS 1 2 6 8 10 18 24 26 30 36 38 42 47 48 49 89 90 92 At a Glance CEO CSR 2014 3 12 3 31 IMSJPM 2014 IMS Health IMS-JPM 2009.4-2014.3 1 1. 1890 120 Santen
サステナビリティ報告書
Living and Working together for the common good. 1 Canon Sustainability Report 2003 Canon Sustainability Report 2003 2 3 Canon Sustainability Report 2003 Canon Sustainability Report 2003 4 93 94 95 96
Nikon 2001ar
Innovations in precision and optical technologies 2001 1 2 5 13 13 16 18 19 20 21 35 36 37 38 39 01 483,957 00 371,801 99 305,765 98 372,146 97 379,089 01 20,911 00 7,770 (18,233) 98 8,318 97 19,936 01
SE-EVカタログ日本語_ indd
特許出願済 特別装備 特許出願 特許出願済 500 型締力の追従性能 型締力 (kn) 400 300 200 100 SE-DU SE-DUZ SE-EV 0 Shot No. 特許出願 特許出願済 日本語 中国語 英語 特別装備 成形機 NC ユニット 特別装備 選択装備 選択装備 Sumitomo Global Web DALIAN KOREA GERMANY TIANJIN SUZHOU
DIGITAL IMAGE INNOVATION Colorio me p4 LP-9000C p6 TV LIVINGSTATION p8
2003 2003 4 1 2004 3 31 DIGITAL IMAGE INNOVATION Colorio me p4 LP-9000C p6 TV LIVINGSTATION p8 ........................................... 1!!!............................. 4.............. 4 LP-9000C......
1 1 14 12 6 137 3 2 15 1 1 5 29 ( 19 3 31 ) 1 2 1-12-32 2021F 5-6-36 3-14 3 361-1 4 4 The Japan Cultural Institute in Rome (The Japan Foundation) Via Antonio Gramsci 74 00197 Roma, Italia The Japan Cultural
1
Eyelet Guide Pig Tail Guide Dog Tail Guide Hook Guide Slit Guide Friction Disc Air Jet Nozzle SPINNING Chip Cutter Air Jet Nozzle Oiling Roller Oiling Nozzle Traverse Guide Technical Information 1 C O
1
ユニシャトル HP 1 2 3 4 5 5.5m 2.5m 20m 6 http://www.muratec.jp http://www.murata-system.co.jp Logistics & Automation Division http://www.muratec.co.jp MURATA MACHINERY, LTD. International Business Dept. Green-Bldg.
Inc.Inc. DBSLtd
P100 P101 P102 P103 P104 P111 99 91 57121 23422 2441 24 510 19930 191116 108 2471 1812 2310 24 4 34 6 12 39 4 12 43 4 45 2 12 47 6 48 6 50 8 Inc.Inc. DBSLtd. 56 3 57 8 5810 2 3 612 11 1 CorporationInc.
6.indd
page 37 page 4 page 14 page 30 3 4 6 8 11 13 14 17 19 22 26 27 30 33 34 37 38 4 // CT * CT * * * 1 // 5 2 6 // 2 // 7 3.5 3.9 3.9 3.5 4.3 5.0 RP NP 3.5 3.5 3.0 8.5 10 11.5 13 15 18 RP 3.9 4.3 5.0 3.4
アニュアルレポート２００３
..................................... 1............................. 2 6 8 10 12 14............................ 16..................... 20.............................. 21.........................................
IP Triple Play Copyright 2006, Allied Telesis Holdings, A rights reserved.
IP Triple Play . 1982 LAN LAN 1987 3 Norway Sweden Allied Telesyn Inc. United States* Mexico Canada Corporate Head Office Regional Head Office Engineering Locations Manufacturing Locations All other
CSR Report Corporate Social Responsibility Report 2010 48 27 30 20 30 30 22331 223 221947725 291954113 689,500 23,781,394 1,295656 23, 775 738 565 2,630 34,837 26,637
14ms(300mm/s) V:300mm/s 0 0.6 0.5 0.4 0.3 /X=2.06% 7.5 7.3 7.1 6.9 6.7 Range=0.01mm 0.2 6.5 75 70 65 8.5 8.3 8.1 7.9 60 7.7 55 7.5 4 0 0.5 1.0 182mm 155mm Intelligent Information for Injection 5 SK open
8% No
Our vision... 24 24 3 8% No.1 3... 4 23-25... 6... 6... 8... 12... 14... 15... 16... 24... 25... 26... 28... 29... 53... 54... 55 for growth Santen Annual Report 24 1 for the future 2 Santen Annual Report
Profile 1927 12 1958 1969 PT MANDOM INDONESIA Tbk 1996 11 2 1978 7 27 1984 7 1 2 3 6 8 8 10 12 14 16 20 22 24 28 30 31 32 34 35
MANDOM Corporation Annual Review 2005 Construct the Foundation for Next Growth Profile 1927 12 1958 1969 PT MANDOM INDONESIA Tbk 1996 11 2 1978 7 27 1984 7 1 2 3 6 8 8 10 12 14 16 20 22 24 28 30 31 32
あいおい損保の現状2001
2 0 0 1 2001 13 8 150-8488 1-28-1 C 03 5424-0101 150-8488 1-28-1 TEL 03 5424-0101 http://www.ioi-sonpo.co.jp (0108) (29-492) 1 2 3 4 5 6 7 9 8 11 10 7 9 19 24 34 43 5 0 / 58 24 8 1231 98 1220 13130 37
1963 1 2 8 12 18 20 22 23 24 6 25 30 54 55
2007 1963 1 2 8 12 18 20 22 23 24 6 25 30 54 55 200720063 2007 2006 2007/2006 2007. 118,139 105,408 12.1% $1,000,754 56,344 46,405 21.4 477,289 32,796 31,502 4.1 277,813 11,836 10,085 17.4 100,267 4,333
日本興亜損保の現状２００８
28 1 NIPPONKOA INSURANCE CONTENTS introduction NIPPONKOA INSURANCE 2 NIPPONKOA INSURANCE 3 NIPPONKOA INSURANCE NIPPONKOA INSURANCE 4 introduction 5 NIPPONKOA INSURANCE NIPPONKOA INSURANCE 6 introduction
Channel to Discovery Plan &
2007 Channel to Discovery Plan & 3 2007 3 2008 1 1 2 6 8 2006 10 14 1 2 16 19 20 22 24 26 28 30 32 34 36 42 43 44 45 70 71 72 2000 10 1 2007 2 2007 2000 10 3 2010 M 2007 M 2010 1,000 2006 2006 M&A 102006
【アニュアルレポート】
Unparalleled Innovation and Customer Satisfaction For Local Communities in Japan and Increasingly Overseas 2012 2012 3 457 BIZ-e- 6 AA Yamato Holdings Co., LTD. 2 4 5 12 14 16 16 18 BIZ- 20 22 e- 24 26
環境報告書
2001 A A Canon Bretagne S.A. France Taiwan Canon Opto(Malaysia) Sdn.Bhd. Malaysia Canon Hi-Tech(Thailand) Ltd. Canon Engineering (Thailand) Ltd.
4 beautiful teeth now 5 6 7 8 9 3.5 mm 3.3 mm 10 11.5 13 15 4.1 mm 3.75 mm 8.5 10 11.5 13 15 18 4 mm 8.5 10 11.5 13 15 18 5.1 mm 5 mm 8.5 10 11.5 13 15 18 10 5.5 mm 7mm 4.1 mm 5.1 mm 3.75 mm 4 mm 5 mm
,889 99, , , ,031 8,952 13,261 16,443 14,464 17,948 % ,037 8,848 10,927
2013 2013 3 3 313 31 2008 2009 2010 2011 2012 90,889 99,764 104,069 103,232 107,031 8,952 13,261 16,443 14,464 17,948 % 9.8 13.3 15.8 14.0 16.8 2,037 8,848 10,927 9,231 12,422 % 2.2 8.9 10.5 8.9 11.6 4,575
4% P % 11.1%1, % %1, %1, % 3.5%1, % %1, % Santen Ph
Financial Section 11 5 54 56 58 59 6 63 http://www.santen.co.jp/ja/ir/document/securities.jsp Santen Pharmaceutical Co., Ltd. Annual Report 215 49 4% 215 3 214 3 P.8 2 98.4% 11.1%1,592 62 12.6% 25 69 1.6%1,618
Contributes to The Health of Individuals Worldwide
ANNUAL REPORT 2008 Annual Report 2008 Our Contribution to Financial and Social Responsibility Contributes to The Health of Individuals Worldwide 2 4 10 16 17 20 22 29 30 32 37 38 40 47 54 64 66 70 102
アニュアルレポート 2001
2001 2001 3 2000 2001 2001/2000 2001 6,686,661 7,314,824 +9.4% $58,518 223,204 225,346 +1.0 1,803 264,310 265,868 +0.6 2,127 121,835 121,227-0.5 970 121,835 16,754-86.2 134 1............................
26 1. 2. 3. 4. 5. Annual Report 26 1 C o n t e n t s... 2... 3 Growth Action 21... 4... 6... 11 At a Glance... 12... 14... 31... 32... 34... 35... 36 CSR... 38... 4... 41... 72... 74... 75 2 3 311 * 26
15690B_表紙1-4.pdf
ISO 14001 ISO 13485:2003 0086 Beautiful Teeth Now...4...5...6...7...8...9...9...10...10....11...11...12...13...14...17...18...23...24...29 1...30 2...32 3...33 4...34...35...39 3 beautiful teeth now 2
2
2 3 2 4 5 6 9 12 12 18 23 47 49 50 52 53 4 5 2007 497,396 21,070 26,038 16,363 536,322 186,528 2007 48.79 12.00 2007 4,213,427 178,481 220,571 138,614 4,53,179 1,580,078 2007 0.41 0.10 2006 451,911 21,947
アニュアルレポート2004
1 2 6 6 8 10 12 14 16 18 18 20 22 28 30 31 32 33 44 45 46 48 49 2004 2003 2002 2001 2000 2004 2004/2003 191,939 167,942 174,218 242,726 174,812 $1,810,745 14.3% 9,600 3,225 140 23,903 (4,628) 90,566 197.7
* ,195,393 1,269,415 $8,987,917 45,664 96, ,338 10,679 50,318 80,293 5,180 25,177 38,947 ** 1,193,011 1,240,008 8,970,008
2002 2002 3 Breakthrough * 3 31 1 2002 2001 2002 1,195,393 1,269,415 $8,987,917 45,664 96,024 343,338 10,679 50,318 80,293 5,180 25,177 38,947 ** 1,193,011 1,240,008 8,970,008 ** 496,826 516,013 3,735,534
7532_0512cj.pdf
6 3 9 6 3 12 31 6 3 UFJ 1-8212 4 5 UFJ 171-858 7 7 UFJ 12-77-696 UFJ 26 25 7 125 12 31 http://www.donki.com/b/ir/ 12-86-449 24 2-6-1163-235 35. 3-5381-7532. 3-5381-766 http://www.donki.com P1 P2 P5 P7
1 20 10 1 21 3 31 1 20 10 1 21 3 31 437444 20 10 121 3 31 1 1 20 10 1 3420 10 121 3 31 4 OEM 100 1 3,097 71 5,495 4 3 90 1414118 41 7 14 19 3 68 9 95 4 66187 95 269 2 PNDGarmin LtdAV 4 2008 2009 3 3 2
Contents 2 8 18 22 24 26 28 30 32 34 36 38 39 40 41 42 48 54 55 75 2 3 4 5 6 7 8 ACT2003 11 12 10 9 8 0 50 70 60 9 10 0 6,000 3,000 9,000 12,000 15,000 11 12 10 9 0 20,000 10,000 30,000 40,000 50,000 11
電気･電子･一般工業用RTVシリコーンゴム
Room Temperature Vulcanizing Rubber C O N T E N T S 3 4 6 8 10 1 1 12 13 14 15 16 18 18 19 19 20 22 23 24 25 26 27 28 29 30 31 1 1 5 2 6 3 7 4 8 3 4 5 KE-42 15 50 C 100%RH KE-489 10 5 0 1 2 3 4 50 C 60%RH
川崎汽船 社会・環境レポート 2008
1 2 3 ➊ ➋ ➌ ❶ ❷ ❸ ❹ ❺ ➊ ➋ ➌ O UTLINE OF B USINESS ➊ ➋ ➌ ➍ ➎ C ORPORATE G OVERNANCE AND R ISK M ANAGEMENT F OR B ETTER R ELATIONSHIP WITH S OCIETY ➊ ➋ ➌ ➍ ➎ ➏ ➐ ➑ ➊ ➋ ➌ ➍ I N T E R V I E W I
WCH_IR2013J_0903fin.pdf
REACHING OUT 2013 REACHING OUT 20133 20143 CONTENTS 02 OUR PRODUCTS 28 LOOKING AHEAD 04 OUR BUSINESSES 201420163 06 OUR OVERSEAS OPERATIONS 32 ONE-ON-ONE DISCUSSION 08 OUR STRENGTHS 16 KEY FIGURES 36 18
ares_018
THE ASSOCIATION FOR REAL ESTATE SECURITIZATION May-June. 2003 1 3 5 11 20 35 37 38 44 58 65 72 80 91 95 104 107 112 2 ARES SPECIAL ARES SYMPOSIUM 2005 November-December. 2005 3 ARES SPECIAL 4 5 November-December.
電気・電子用RTVシリコーンゴム
CONTENTS P3 P4-6 P7-9 P10-11 P12-25 P12-15 P16 P17 P18-19 P20-21 P22-23 P24 P25 P26-27 2 P28 P29 P30 P31 O Si O Si O Si Si O Si O O Si O Si Si O H C H H Si O O Si O O Si H C H H 3 Feature 1 Feature 2 Feature
CONTENTS Vol.02
CONTENTS 3 4 9 15 16 19 21 27 28 29 2Vol.02 INTRODUCTION fr N1 D Hz (1) = [ ] D Fig. 1-3 t D>3t L 1 C 1 R 1 fr N2 Hz l = [ ] (2) C 0 Fig. 1-1 a Fig. 1-4 t >4a a>t fr = 1/ { 2π L1C1} { } fa= 1/ 2π L1C0C1/
NX10_150223J16AB_0116.ai
Park NX10 www.parkafm.co.jp Park Systems The Most Accurate Atomic Force Microscope Park NX10 Park NX10 Park Systems The Most Accurate Atomic Force Microscope Park NX10 nm 12 8 4 0 Park Systems The Most
1. 8. Value Chain 10. At a Glance
Annual Report 2007 1. 8. Value Chain 10. At a Glance 12. 14. 18. 23. 33. 41. 48. 49. 50. 51. HOUSING MARKET Market trends are not promising but there are many opportunities for our growth 1 () 128 127
QX/..../IG/P1.`19/F
President s Message (https://www.aozoraclub.com/ http://www.aozorabank.co.jp/ http://www.aozora-invest.co.jp/ (http://www.svb.com/) http://www.net-daibiki.com/ ... 34... 35...
businessreport_cover
41331 3 331 33193 28 Business Report 21.4.1 211.3.31 6727 533 31 183-871 11 12-176-417 http://www.sumitomotrust.co.jp/sta/retail/ service/daiko/index.html IR http://wacom.jp/jp/company/ 349-1148511 TEL48-78-1211FAX48-78-122
1. 2. 3. 4. 5. Contents The Asahi Kasei History... 1... 4... 5 Growth Action 21... 6... 12 At a Glance... 14... 16... 32 CSR... 36... 38... 39... 7...
27 27 1. 2. 3. 4. 5. Contents The Asahi Kasei History... 1... 4... 5 Growth Action 21... 6... 12 At a Glance... 14... 16... 32 CSR... 36... 38... 39... 7... 72... 73 The Asahi Kasei History 1922 1931 199199
A-FR
11 12 > 17 13 14 http://store.uniqlo.com/jp/ http://www.uniqlo.com/jp/corp/customer 15 16 LONDON PARIS SHANGHAI 18 100 80 94 60 54 40 39 30 20 9 11 9 14 0 02 03 04 05 06 07 08 09 HONG KONG SEOUL NEW YORK
CONTENTS CEO CSR 3 31 IMSJPM 213 IMS Health IMS-JPM
Eyeing Further 213 213 3 Specialization CONTENTS 1 2 4 6 12 18 2 24 3 32 36 4 41 77 78 8 CEO CSR 3 31 IMSJPM 213 IMS Health IMS-JPM 28.4-213.3 1 1. 189 189 12 P.12 P.24 8.3% 2 1 No.2 39.7% 5.4% No.2 19.1%
Corporate Philosophy Otsuka-people creating new products for better health worldwide
ANNUAL REPORT 2013 Corporate Philosophy Otsuka-people creating new products for better health worldwide 00 13 44 Contents 02 14 48 03 16 54 04 22 59 06 30 76 08 36 78 10 38 79 12 41 Group Structure ur
Components Components Report CC
Components Components Report CC-1143 2 1 2 3 30% 3%FS 50msec 4 5 EVD-1000 Rc1/4 60,400R 100,500,900kPa 42 100 EVD-1000 EVD-3000 1500 400 900 kpa 900 kpa 500 kpa 500 kpa 100 kpa 100 kpa 700 60 Rc1/4 Rc1/4
ニコンレポート2016
NIKON REPORT 216 216 216 3 1 2171 19171 216 3Next 1 - Transform to Grow 6 216 2171215 1 http://www.nikon.co.jp/profile/museum/ ABOUT NIKON 2 4 6 BUSINESS STRATEGY 8 9 14 16 BUSINESS PERFORMANCE 18 22 216
Contents 1 Contents 1 2 USB3.0 Connectors Plug Cables USB Connectors Mini-B Receptacles 3 Plugs HDMI Connectors Type E Receptacles 6 Plu
ELECT R ONIC COMPONENT S IFC07 B-03 USB Connectors HDMI Connectors DisplayPort Connectors Contents 1 Contents 1 2 USB3.0 Connectors Plug Cables 2 3 4 USB Connectors Mini-B Receptacles 3 Plugs 4-5 6 7 HDMI
ParkOptions&ACC_2001_Jap.ai
Park AFM www.parkafm.co.jp Park AFM 02 Park Systems Enabling Nanoscale Advances 04 06 08 10 11 12 14 15 16 18 19 03 Park AFM SmartScan TM 04 Park Systems Enabling Nanoscale Advances 05 Park AFM 06 Park
Ł\”ƒ1
341331 2 9,869 9,838 0 2,500 5,000 7,500 10,000 12,500 315 703 189 200 0 200 400 600 800 11,441 3 14.1% 32.7% 19.5% 16.2% 17.5% 1 3 3 4 5 5 6 160,937 15,305 271,220 25,830 29,812 132,774 (1,411) 266,015
untitled
2009 PR-D391 Ver.2 09.01.025.A contents welcome 2 philosophy 4 dental 6 surgical 8 industrial 10 research & development 12 production 14 global sales 16 environment 18 history 20 products 22 companies
ニコン レポート 2014
NIKON REPORT 2014 2014 20143 2014 20153 CSR CONTENTS 02 04 06 08 09 14 Next 100 - Transform to Grow 18 18 20 22 FPD 24 26 28 30 31 32 FOCUS CSR 34 CSR 36 38 39 41 42 CSR 44 46 48 52 57 58 60 61 01 P.67
untitled
High Performance Mass Flow Controller 45 45 s G H T W I A B C D E F G T D W I F E H+6 H SEC SEF -Z512KX SEC SEF -Z512 MG X SEC SEF -Z522 MG XN SEC SEF -Z532MGX N SEC SEF -Z542MGX N SEC SEF -Z552MGX
1120再入稿_Ushio_ウシオ電機_53中期_株主通信.indd
PRISM 2015 4 12015 9 30 2015 12 CONTENTS USHIO NOW! P 2 P 4 P 6 P 8 P10 P12 P14 USHIO NOW! 1964 No. 1 1964 3 19,556 2015 9 30 5,764 1,749 853 3,162 2015 4 12015 9 30 886 441 387 479 20 65 4 5 2 USHIO NOW!
あいおい損保の現状 2005
2 3 0 2,000 4,000 6,000 8,000 10,000 8,368 8,278 8,365 0 60 65 70 60.06 60.80 64.58 4 0 30 35 40 35.29 33.45 33.15 20,000 10,000 0-10,000 7,335 9,924 13,044 5 50,000 25,000 0 20,319 22,394 45,324 40,000
http://www.softbank.co.jp/ The No.1 Name in Broadband ANNUAL REPORT 2003 Contents 2 4 The Reason why SOFTBANK is No.1 in the Broadband Market 12 13 54 55 21 1876 1941 1970 IT20 ADSL Yahoo! BB No.1 2003
M&A / & 18 &
2005 1 23 2 24 6 26 8 9 10 M&A / 14 16 & 18 & 20 22 32 33 34 51 52 53 2000 10 3 2005 1 2010 1,000 2000 10 2001 8 M 2005 34 2010 1,000 45,000 37,005 40,091 30,000 22,654 15,000 14,346 0 1,351 2000 2001
2013 London New York Paris 2013 Tokyo Singapore
01 London New York Paris 01 Tokyo Singapore 01 10 Global Power City Index GPCI 008 Global Power City Index GPCI-01 GPCI YEAR BOOK 01 Global Power City Index GPCI 1... 40 6 4 5 4. 5. Global Power City
1 2 3
1 2 3 2. 3. 1 2 3 2. 2 3 4 5 1 2 3 4 2. 1 2 3 4 5 6 7 1. 2. 4. 1 2 5. 3 4 .5 52. 53 1.53 53 55 56 57 60 2.64 3.64 4.65 5.66 66 67 68 6.74. 75 1.75 75 75 76 77 78 2.80 80 80 80
2004 2004 41 2005 331 Exceed Your Vision VisionExceed 14......................... 01... 04................. 08......................... 12............................. 14......................... 16........................
100 3 100 Contents 2 4 6 8 12 UA 16 3 17 18 EC 20 22 24 26 30 32 38 5 44 11 46 2017 2017 IIRC 4 13 31 2017 3 IR www.united-arrows.co.jp/ir/lib/index.html P38 5 2 3 1 2 3 VISION VOICE VISUAL 1989 1995 2001
RES009_05.indd
AC100V 10V 1.62.0 Cu 0 40 90 100V L E DLED MA-500- MA-R- 500W 50/60Hz 1 MA-600- MA-R- 600W 50/60Hz 1 HWD-4NE-JA 1 1 HD-RD- 400W 50/60Hz 1 2 3 HWD-5ND-JA HD-RD- 500W 50/60Hz 1 2 3 MA-R- 1 DV-503P- 1 DV-3PS-
年 3 月期
214 214 年 3 月期 1 巻頭特集 6 6 年間の主要財務指標 8 株主の皆様へ 12 特集グローバルサプライチェーン構築の取り組み モダニゼーション事業の状況 16 営業概況 25 CSR 28 コーポレート ガバナンス 3 取締役 監査役 執行役員 32 財務セクション 33 財政状態および経営成績の検討と分析 36 連結貸借対照表 38 連結損益計算書 39 連結包括利益計算書 4 連結株主資本等変動計算書
2 1 B VCCI-B Cintiq Wacom Adobe Adobe Photoshop Microsoft Windows Apple Apple Mac TM Cintiq 13HD Version 1.0, Rev C Wacom Co., Ltd. All right
1 Cintiq 13HD DTK-1300 1 2 1 B VCCI-B Cintiq Wacom Adobe Adobe Photoshop Microsoft Windows Apple Apple Mac TM Cintiq 13HD Version 1.0, Rev C0413 2013 Wacom Co., Ltd. All rights reserved. 2 Contents Index
untitled
2006 One Company 62,028372,669 WINWIN M&AOne Company 1997200610% 15%2010121,50010%ROE 11% 200532020063201231 2005.3 2006.3 2006.12 2006.12 % 92,492 9,373 10.1 6,105 2,290 3,524 3,956 2,944 5,636 105,665
アニュアルレポート2008
2008 2008 3 Moving Forward with the Global Subaru Identity page 2-7 page 8-15 page 16-17 page 18 page 19-21 page 22-23 page 24 page 25-33 page 34 page 35 Corporate Social Responsibility, CSR 9 1917 360
大和ハウスグループ アニュアルレポート2009
CEO COO CFO 18 19 Dear Stakeholders Building a New Era with Heart 20 2008 4 2 3 Challenge 2010 2008 35.3% GDP 2008 1.1% 1 6,909 5 6 735 817.4% 398 5 535.0% 41 768.1% ROE 0.7%9.0% 1 24 22009 20207 9 1002055
コーポレート・データ_損保ジャパン日本興亜の現状2016
184 186 188 190 191 193 194 195 198 2016 183 2014 9 9 NKSJ 11 2015 2016 3 5 10 SOMPO 5 2002 7 7 2003 2004 2005 8 12 4 7 9 DC100% 4 6 10 12 PICC Holding Company 4 6 7 7 7 10 11 2010 2011 3 OJSC IC ROSNO
株式会社良品計画_会社案内 2019（日本語）
Corporate Profile 219 English 198 12 47, 29 9 19893 217 5, 6ROE15% 4 219 4 MUJI Diner MUJI HOTEL GINZA 17 8424 26 3 3 3989 443 https://ryohin keikaku.jp/ 1989 6 1979 5 MUJI HOUSE MUJI (HONG KONG) CO.,
<836F F332E706466>
DC Power Jacks DCP0 B-0 Contents Contents & Specifications DC Power Jacks( RC-0A Standard) Product Lineup DC Power Jacks DC Power Jacks Product Lineup DC Power Jacks Specifications Insulation Resistance
Vision and Strategy IP 1 Fields: An Evolving History 5 9 11 Performance 17 18 At a Glance 20123 18 19 19 22 25 Sustainability CSR 27 32 Financial Sect
We Make It Happen 2012 2011412012 331 Vision and Strategy IP 1 Fields: An Evolving History 5 9 11 Performance 17 18 At a Glance 20123 18 19 19 22 25 Sustainability CSR 27 32 Financial Section 39 49 51
Company Profile 2014 Core Hybrid 48 33 ESPEC Group ESPEC EUROPE GmbH(Germany) ESPEC KOREA CORP. ESPEC (CHINA) LIMITED ESPEC SOUTH EAST ASIA SDN. BHD. ESPEC NORTH AMERICA, INC. ESPEC
Preface The semiconductor industry has developed remarkably with the rapid progress of micro electronics technology. TANAKA DENSHI KOGYO K.K. has grow
Preface The semiconductor industry has developed remarkably with the rapid progress of micro electronics technology. TANAKA DENSHI KOGYO K.K. has grown in line with global expansion of the semiconductor
RISO P ‘C’³
RISO REPORT 2000 1 2 3 4 5 6 T O P I C S 7 8 T O P I C S 39 100,000 12,000 6,000 80,000 60,000 40,000 20,000 10,000 8,000 6,000 4,000 2,000 5,000 4,000 3,000 2,000 1,000 0 0 0 H8/3 H9/3 H10/3 H11/3 H12/3
アニュアルレポート 2000
2000 2000 3 3 31 1 : : 1 1 1999 2000 2000/1999 2000..................... 6,804,182 6,686,661 1.7% $63,082............................... 348,212 240,627 30.9 2,270............................. 377,691
KOMORI KOMORI Komori Total Solutions 1 2 KOMORI DPS
217 217 3 Kando : Beyond Expectations KOMORI 1923 9 KOMORI Komori Total Solutions 1 2 KOMORI 4 5 1 DPS 12 13 14 6 15 18 23 24 3 31 215 216 217 217/216 91,259 95,326 86,618 9.1% 6,489 6,612 1,712 74.1 7,841
* Contents 1 2 CEO 4 CEO 5 : Reaching Out Globally 9 13 120 14 16 19 20 24 25 25 26 28 30 31 61 62 63 3 31 IMSJPM MIDAS 2006.1-2010.3
2010 for the Future Reaching Out 2010 2010 3 * Contents 1 2 CEO 4 CEO 5 : Reaching Out Globally 9 13 120 14 16 19 20 24 25 25 26 28 30 31 61 62 63 3 31 IMSJPM MIDAS 2006.1-2010.3 3 31 2010 2009 2010/2009